

Embargoed until: November 5, 2019, 7 a.m. CET

November 5, 2019

Key Financial Data: Third quarter 2019

Evonik confirms full-year earnings outlook despite ongoing weakness in global economy

Tim Lange
Head of Investor Relations
Phone +49 201 177-3150
tim.lange@evonik.com

- 2019: Adjusted EBITDA to remain at least stable
- Free cash flow outlook for full year confirmed and specified: around €700 million
- Q3: Sales and operating earnings below year-ago period
- Stricter cost discipline supports earnings

Essen, Germany. Evonik is sticking to its full-year earnings outlook despite an ongoing weakness in the global economy. The company expects adjusted EBITDA to remain at least stable compared with last year. Sales are now expected to be slightly lower than the previous year because of lower demand. Evonik had expected sales to remain stable. In 2018 Evonik generated – excluding the divested Methacrylates business – sales of €13.3 billion and adjusted EBITDA of €2.15 billion.

“We prepared ourselves at an early stage with stricter cost discipline and additional contingency measures for a cooling global economy,” said Christian Kullmann, chairman of Evonik’s executive board. “We are being very proactive to ensure we meet our full-year outlook.”

The 2018 initiated efficiency program to reduce administrative and selling expenses by €200 million annually has been accelerated. By end of this year, Evonik will achieve €120 million of savings, €20 million more than originally planned. A further €20 million will be saved with additional contingency measures such as delaying new hires and more restrictive expenditure on external services.

Evonik is specifying its full-year outlook for free cash flow and is now expecting a level of around €700 million, a significantly higher free cash flow compared with last year. This is mainly due to lower capex spending, less build-up of net working capital and the partial reimbursement of pension payments from the

Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
Fax +49 201 177-3475
www.evonik.com

Supervisory Board
Bernd Tönjes, Chairman
Executive Board
Christian Kullmann, Chairman
Dr. Harald Schwager, Deputy Chairman
Thomas Wessel, Ute Wolf

Registered Office is Essen
Register Court Essen Local Court
Commercial Registry B 19474

Contractual Trust Arrangement (CTA). The more precise outlook does not include taxes incurred from the carve out of the divested Methacrylates business.

The global economic slowdown continued to impact Evonik's performance in the third quarter. In the months July to September sales fell 3 percent to €3.23 billion due to lower volumes and selling prices. Adjusted EBITDA fell 6 percent year-on-year to €543 million.

Segment Performance

Resource Efficiency: Segment sales declined 1 percent to €1.4 billion in the third quarter. Coatings as well as the adhesive and resins business was affected by the global economic slowdown, especially in the automotive and coatings sector. Sales volumes declined for industry-related silica applications. In contrast, high-performance polymers benefited from solid demand for membranes and from the 3D printing industry. Crosslinkers saw high demand from the wind industry. Adjusted EBITDA dropped 4 percent to €322 million.

Nutrition & Care: Sales declined 2 percent to €1.14 billion in the third quarter. Demand for essential amino acids for animal nutrition remained high while selling prices declined further. In the Health Care business sales increased, especially due to good demand for pharma and food ingredients. Sales increased significantly for polyurethane-foam additives, mostly on high demand for durable consumer goods and insulation. Adjusted EBITDA at the segment dropped 11 percent to €188 million.

Performance Materials: Sales in the third quarter decreased 20 percent to €475 million compared with the prior-year quarter. Development at Performance Intermediates was impaired by a lower oil and naphtha price and slightly lower selling prices. Continuing constraints in raw-material supply and technical problems at the C4 plants in Marl and Antwerp weighed on earnings. At Functional Solutions the alkoxides business developed well. Adjusted EBITDA declined 25 percent to €47 million at the segment.

Evonik Group: Excerpt from the income statement

(in € million)	Q3 2019	Q3 2018	Change in %	1-9 2019	1-9 2018	Change in %
Sales	3,232	3,347	-3%	9,824	10,007	-2%
Adjusted EBITDA	543	579	-6%	1,647	1,748	-6%
Adjusted EBIT	293	376	-22%	948	1,161	-18%
Adjustments	-74	-12		-114	-47	
Financial result	-7	-38		-112	-133	
Income before income taxes, continuing operations	212	326	-35%	722	981	-26%
Income taxes	-54	-51		-155	-236	
Income after taxes, continuing operations	158	275	-43%	567	745	-24%
Income after taxes, discontinued operations	1,326	59		1,395	198	
Income after taxes	1,484	334	344%	1,962	943	108%
thereof attributable to non-controlling interests	5	5		17	15	
Net Income	1,479	329	350%	1,945	928	110%
Adjusted net income	195	307	-36%	671	847	-21%

Prior-year figures restated

Segment performance

(in € million)	Sales			Adjusted EBITDA		
	Q3 2019	Q3 2018	Change in %	Q3 2019	Q3 2018	Change in %
Nutrition & Care	1,138	1,167	-2%	188	212	-11%
Resource Efficiency	1,414	1,425	-1%	322	335	-4%
Performance Materials	475	591	-20%	47	63	-25%
Services	196	161	22%	32	39	-18%
Other operations	9	3		-46	-70	
Group	3,232	3,347	-3%	543	579	-6%

(in € million)	Sales			Adjusted EBITDA		
	1-9 2019	1-9 2018	Change in %	1-9 2019	1-9 2018	Change in %
Nutrition & Care	3,418	3,474	-2%	558	643	-13%
Resource Efficiency	4,297	4,306	0%	977	1,027	-5%
Performance Materials	1,548	1,727	-10%	174	194	-10%
Services	542	489	11%	99	99	0%
Other operations	19	11		-161	-215	
Group	9,824	10,007	-2%	1,647	1,748	-6%

Prior-year figures restated

Employees by segment

	30.09.2019	31.12.2018
Nutrition & Care	8,107	8,218
Resource Efficiency	10,221	10,085
Performance Materials	1,645	1,724
Services	12,088	12,091
Other operations	509	505
Continuing operations	32,570	32,623
Discontinued operations	-	3,420
Evonik	32,570	36,043

Prior-year figures restated

Company information

Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-oriented innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik's corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world. In fiscal 2018, the enterprise with more than 32,000 employees generated sales of €13.3 billion and an operating profit (adjusted EBITDA) of €2.15 billion from continuing operations.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.